% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sachpekidis:275626,
      author       = {C. Sachpekidis$^*$ and V. Weru$^*$ and A.
                      Kopp-Schneider$^*$ and J. C. Hassel and A.
                      Dimitrakopoulou-Strauss$^*$},
      title        = {{T}he prognostic value of [18{F}]{FDG} {PET}/{CT} based
                      response monitoring in metastatic melanoma patients
                      undergoing immunotherapy: comparison of different metabolic
                      criteria.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {50},
      number       = {9},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2023-00828},
      pages        = {2699-2714},
      year         = {2023},
      note         = {#EA:E060#LA:E060# / 2023 Jul;50(9):2699-2714},
      abstract     = {To investigate the prognostic value of [18F]FDG PET/CT as
                      part of response monitoring in metastatic melanoma patients
                      treated with immune checkpoint inhibitors (ICIs).Sixty-seven
                      patients underwent [18F]FDG PET/CT before start of treatment
                      (baseline PET/CT), after two cycles (interim PET/CT) and
                      after four cycles of ICIs administration (late PET/CT).
                      Metabolic response evaluation was based on the conventional
                      EORTC and PERCIST criteria, as well as the newly introduced,
                      immunotherapy-modified PERCIMT, imPERCIST5 and iPERCIST
                      criteria. Metabolic response to immunotherapy was classified
                      according to four response groups (complete metabolic
                      response [CMR], partial metabolic response [PMR], stable
                      metabolic disease [SMD], progressive metabolic disease
                      [PMD]), and further dichotomized by response rate
                      (responders = [CMR] + [PMR] vs. non-responders = [PMD] +
                      [SMD]), and disease control rate (disease control = [CMR] +
                      [PMR] + [SMD] vs. [PMD]). The spleen-to-liver SUV ratios
                      (SLRmean, SLRmax) and bone marrow-to-liver SUV ratios
                      (BLRmean, BLRmax) were also calculated. The results of
                      PET/CT were correlated with patients' overall survival
                      (OS).Median patient follow up $[95\%$ CI] was 61.5 months
                      [45.3 - 66.7 months]. On interim PET/CT, the application of
                      the novel PERCIMT demonstrated significantly longer survival
                      for metabolic responders, while the rest criteria revealed
                      no significant survival differences between the different
                      response groups. Respectively on late PET/CT, both a trend
                      for longer OS and significantly longer OS were observed in
                      patients responding to ICIs with metabolic response and
                      disease control after application of various criteria, both
                      conventional and immunotherapy-modified. Moreover, patients
                      with lower SLRmean values demonstrated significantly longer
                      OS.In patients with metastatic melanoma PET/CT-based
                      response assessment after four ICIs cycles is significantly
                      associated with OS after application of different metabolic
                      criteria. The prognostic performance of the modality is also
                      high after the first two ICIs cycles, especially with
                      employment of novel criteria. In addition, investigation of
                      spleen glucose metabolism may provide further prognostic
                      information.},
      keywords     = {Immune checkpoint inhibitors (ICIs) (Other) / Immunotherapy
                      (Other) / Metabolic response criteria (Other) / Metastatic
                      melanoma (Other) / Treatment response evaluation (Other) /
                      [18F]FDG PET/CT (Other)},
      cin          = {E060 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37099131},
      doi          = {10.1007/s00259-023-06243-y},
      url          = {https://inrepo02.dkfz.de/record/275626},
}